Cholinergic Abnormalities, Endosomal Alterations and Up-Regulation of Nerve Growth Factor Signaling in Niemann-Pick Type C Disease
- Carolina Cabeza1, 4,
- Alicia Figueroa†1, 4,
- Oscar M Lazo†1, 4,
- Carolina Galleguillos1, 4,
- Claudia Pissani1, 4,
- Andrés Klein3,
- Christian Gonzalez-Billault5,
- Nibaldo C Inestrosa2, 4,
- Alejandra R Alvarez2,
- Silvana Zanlungo3 and
- Francisca C Bronfman1, 4Email author
© Cabeza et al; licensee BioMed Central Ltd. 2012
Received: 4 August 2011
Accepted: 29 March 2012
Published: 29 March 2012
Neurotrophins and their receptors regulate several aspects of the developing and mature nervous system, including neuronal morphology and survival. Neurotrophin receptors are active in signaling endosomes, which are organelles that propagate neurotrophin signaling along neuronal processes. Defects in the Npc1 gene are associated with the accumulation of cholesterol and lipids in late endosomes and lysosomes, leading to neurodegeneration and Niemann-Pick type C (NPC) disease. The aim of this work was to assess whether the endosomal and lysosomal alterations observed in NPC disease disrupt neurotrophin signaling. As models, we used i) NPC1-deficient mice to evaluate the central cholinergic septo-hippocampal pathway and its response to nerve growth factor (NGF) after axotomy and ii) PC12 cells treated with U18666A, a pharmacological cellular model of NPC, stimulated with NGF.
NPC1-deficient cholinergic cells respond to NGF after axotomy and exhibit increased levels of choline acetyl transferase (ChAT), whose gene is under the control of NGF signaling, compared to wild type cholinergic neurons. This finding was correlated with increased ChAT and phosphorylated Akt in basal forebrain homogenates. In addition, we found that cholinergic neurons from NPC1-deficient mice had disrupted neuronal morphology, suggesting early signs of neurodegeneration. Consistently, PC12 cells treated with U18666A presented a clear NPC cellular phenotype with a prominent endocytic dysfunction that includes an increased size of TrkA-containing endosomes and reduced recycling of the receptor. This result correlates with increased sensitivity to NGF, and, in particular, with up-regulation of the Akt and PLC-γ signaling pathways, increased neurite extension, increased phosphorylation of tau protein and cell death when PC12 cells are differentiated and treated with U18666A.
Our results suggest that the NPC cellular phenotype causes neuronal dysfunction through the abnormal up-regulation of survival pathways, which causes the perturbation of signaling cascades and anomalous phosphorylation of the cytoskeleton.
Neurotrophins (NGF, BDNF, NT3 and NT4) regulate different aspects of the developing and mature nervous system, including neuronal survival and neuronal morphology. These small proteins exert these effects by binding to members of the Trk family of receptor tyrosine kinases (TrkA, TrkB and TrkC) or to the p75 neurotrophin receptor (p75). Whereas p75 binds all neurotrophins, in addition to other ligands (e.g., proneurotrophins and amyloid peptides), each Trk binds preferentially to its cognate neurotrophin. For example, TrkA, TrkB and TrkC bind NGF, BDNF and NT3, respectively [1–3].
Several neurodegenerative diseases are produced by alterations in molecules related to endocytosis and vesicular trafficking, which are cellular processes that regulate neurotrophin signaling [4, 5]. Therefore, one possible target of endosomal abnormalities and trafficking defects is neurotrophin signaling [6, 7].
Niemann-Pick type C (NPC) disease is a fatal autosomal recessive disorder resulting from mutations in the NPC1 (in 95% of patients) or the NPC2 gene (in 5% of patients). The loss of NPC1 or NPC2 function causes the accumulation of cholesterol and glycosphingolipids in the late endocytic pathway. Some evidence has suggested that the accumulation of cholesterol and other lipids inside the cell results in endosomal abnormalities, including alterations in the recycling pathway and alterations in late endosome dynamics, in addition to the down-regulation of neurotrophic signaling [8–17]. Although most mammalian cells are affected by intracellular cholesterol overload, neurodegeneration is the main cause of fatality in patients with NPC disease [8, 10].
NPC disease shares several similarities, including late endosomal and lysosomal abnormalities, neurofibrillary tangles and cognitive impairment, with other neurodegenerative disorders, such as Alzheimer's disease (AD) [18, 19]. A typical NPC patient will develop cerebellar ataxia and progressive cognitive deterioration, in addition to compromised organ function [8, 11, 20]. In AD, cognitive impairment is correlated with neurodegeneration of the central cholinergic system. Basal forebrain cholinergic neurons account for most of the cholinergic innervation of the hippocampus and cortical mantle and play a key role in the regulation of synaptic activity and the modulation of memory and attention [21–24]. Derangement of the cholinergic system is one of the pathological hallmarks of AD and contributes to the progressive cognitive deterioration of AD patients . NPC patients also show cognitive decline , but no study has examined the possible causes underlying the neuropathological alterations associated with cognitive impairment in this disease [26, 27].
The aim of this work was to assess whether the endosomal alterations that are observed in mouse and cellular models of NPC disease disrupt NGF signaling. We used two different models: NPC1-deficient (NPC1-/-) mice and PC12 cells treated with U18666A (PC12-U18666A cells), a well-known inducer of the NPC phenotype [28–31]. Contrary to our expectations, NGF signaling was up-regulated or conserved in both models of NPC, suggesting that neurodegeneration in NPC may result from the misregulation of kinase cascades triggered by neurotrophins as well as other trophic factors.
Goat polyclonal anti-ChAT antibody was obtained from Chemicon (Temecula, CA, USA). Rabbit polyclonal anti-p75, mouse monoclonal anti-PLCγ and rabbit polyclonal anti-TrkA antibodies were obtained from Upstate Biotech (Charlottesville, USA). Mouse monoclonal anti-tau (AT8) and mouse monoclonal anti-Flag antibodies were obtained from Pierce (Rockford, Illinois, USA). Mouse monoclonal anti-neurofilament antibody was obtained from Sigma (St. Louis, Missouri, USA). Biotinylated secondary antibodies against rabbit and mouse IgG and protease-free serum bovine albumin (BSA) were obtained from Jackson ImmunoResearch (West Grove, Pennsylvania, USA). The following were obtained from Molecular Probes (Invitrogen, Maryland, USA): mouse monoclonal antibody against Alexa Fluor 488; Alexa Fluor 488 carboxylic acid, 2,3,5,6-tetrafluorophenyl ester (Alexa Fluor 488 5-TFP); transferrin conjugated to Alexa Fluor 568; phalloidin Alexa Fluor 546; LysoTracker Red DND-99; Alexa Fluor 488-conjugated donkey anti-rabbit antibody; Alexa Fluor 594-conjugated donkey anti-goat antibody; Alexa Fluor 488-conjugated donkey anti-mouse antibody; and Alexa Fluor 555-conjugated cholera toxin subunit-B (CT-B). NGF was obtained from Alamone Labs (Jerusalem, Israel). ALZET Osmotic pumps (model 1002) were obtained from Alza Corp. (Palo Alto, California, USA). The ABComplex-peroxidase kit and 3-'3-diaminobenzidine were obtained from DakoCytomation (California, USA). Mowiol and phosphatase inhibitor cocktail were obtained from Calbiochem (San Diego, California, USA). Wortmannin was obtained from Sigma-Aldrich (St. Louis, USA). U18666A was obtained from Biomol (Plymouth Meeting, Pennsylvania, USA). Phospho-PLC-γ rabbit polyclonal, phospho-ERK1/2 rabbit polyclonal, ERK1/2 rabbit polyclonal and Akt rabbit polyclonal antibodies were obtained from Cell Signaling (Beverly, Massachusetts, USA). Phospho-Akt rabbit polyclonal antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, California, USA). The protease inhibitor cocktail was obtained from Roche (Hertfordshire, UK). All other reagents were obtained from Sigma (St. Louis, Missouri, USA). The plasmid for Rab7-GFP was a gift from Cecilia Bucci (University of Salento, Lecce, Italy). The plasmid for Rab5-GFP was a gift from Victor Faundez (Emory University, USA). The plasmid for TrkA-Flag was a gift from Francis Lee (Cornell University, NY, USA).
BALB/c mice carrying a heterozygous mutation in the Npc1 gene were kindly donated by Dr. Peter Pentchev (U.S. National Institutes of Health, Bethesda, MD, USA). The genotypes were determined by polymerase chain reaction (PCR)-based screening as described previously . All animal protocols were approved by the Animal Studies Review Board of our institution.
Mice were anesthetized with a mixture of xylazine (12 mg/kg) and ketamine (80 mg/kg) administered i.p., and 9% lidocaine was applied locally to the ears. Mice were then positioned in a stereotaxic apparatus, and coordinates were calculated based on the Franklin and Paxinos atlas of the mouse brain . After surgery, the animals were injected i.p. with the antibiotics ketoprofen (2.5 mg/kg) and enrofloxacin (5 mg/kg) for four days and maintained under observation and temperature control for one week. For histological preparation of brain tissue, anesthetized mice were transcardially perfused with 40 ml of 0.9% NaCl and 20 ml of 4% paraformaldehyde (PFA) in phosphate buffer. After extraction, the brain was post-fixed overnight in 4% PFA, left in 30% sucrose for 24 hrs, and coronally sectioned (40 μm) on a cryostat.
Fimbria-fornix transection and intracerebroventricular infusion of NGF
Unilateral axotomy of the septo-hippocampal pathway was induced by aspirative lesion of the fimbria-fornix as previously described . In brief, anesthetized mice were positioned in a stereotaxic apparatus, and a small piece of skull was removed at the stereotaxic coordinates 0.6 mm caudal to the bregma and 0.0-2.0 mm lateral to the midline. After excision of the dura, we performed a syringe aspiration of the dorsal fornix-fimbria with a 5-ml syringe fitted with a 25 G 5/8" needle. We also used the syringe to aspirate part of the cingulate and parietal cortices. Mice were sacrificed 7 days after axotomy.
Artificial cerebrospinal fluid (ACSF; 150 mM NaCl, 1.8 mM CaCl2, 1.2 mM MgSO4, 2 mM KH2PO4 and 10 mM glucose, pH 7.4) with or without 20 μg/ml NGF (100 μl per osmotic pump) was infused for 7 days with a brain infusion kit (Alza Corp.) connected to a model 1002 ALZET osmotic pump, as described previously . The cannulae and connector tubes were filled with ACSF or ACSF plus NGF and attached to a filled pump. Using the arm of the stereotaxic apparatus, each cannula was lowered into the brain at the coordinates of the left ventricle (0.2 mm caudal to bregma, 0.8 mm to the midline of the contralateral side and 1.8 mm ventral to the brain surface). The cannula was anchored to the skull with a screw and glued with dental acrylic. Axotomized mice were infused with NGF for 7 days immediately following axotomy.
AChE enzyme histochemistry
Serial coronal cryostat sections (40 μm) were collected in 0.1 M phosphate buffer (pH 7.4), washed in 65 mM sodium maleate (pH 6.0) and incubated as floating sections for staining for 1 hr at room temperature (RT) in a solution containing 0.05 mg/mL acetylthiocholine iodide, 0.1 mM tetra-isopropyl-pyrophosphatamide, 0.05 mM potassium ferricyanide, 0.3 mM CuSO4, 0.5 mM sodium citrate and 65 mM sodium maleate (pH 6.0), as described previously .
Immunohistochemistry of brain sections
Immunohistochemistry was performed as follows: (i) 15 min incubation in 0.03% H2O2 in 0.1 M Tris-HCl, and 150 mM NaCl, pH 7.4 (TBS) to block endogenous peroxidase; (ii) 30 min incubation at 4°C in 0.4% Triton X-100 in TBS; (iii) 1.5 hr incubation at 4°C in 0.2% Triton X-100, 5% fetal calf serum (FCS) and 5% BSA in TBS; (iv) 24 hr incubation at 4°C with primary antibody in TBS plus 0.2% Triton-X100 and 5% FCS; (v) 1.5 hr incubation at RT with biotin-conjugated secondary antibody; and (vi) 1 hr incubation with peroxidase-conjugated avidin ABC (DakoCytomation), followed by visualization of peroxidase activity with diaminobenzidine (DAB, 1 mg/mL) and 0.01% H2O2 in TBS. Primary antibodies were used at the following dilutions: anti-ChAT (1:300), anti-p75 (1:500) and anti-neurofilament (1:2000). Sections were immediately rinsed in distilled water, mounted, air-dried, cleared with xylene and mounted in Entellan.
Immunofluorescence of brain sections
Single or double immunofluorescence was performed in floating brain sections as follows: (i) 15 min incubation in TBS; (ii) 15 min incubation in 0.15 M glycine in TBS; (iii) 15 min incubation in TBS; (iv) 10 min incubation in NaBH4 (10 mg/ml) in TBS; (iii) 30 min incubation at 4°C in 0.3% Triton X-100 in TBS; (iv) 1.5 hr incubation at 4°C with 0.2% Triton X-100, 5% FCS, and 2% BSA in TBS; (v) 15 min incubation in TBS; (vi) 24 hr incubation at 4°C with primary antibodies in 0.2% Triton X-100, 5% FCS and 2% BSA in TBS; (vii) 15 min incubation in TBS; and (vii) 1.5 hr incubation at RT with fluorochrome-conjugated 2% BSA in TBS. Sections were immediately rinsed in distilled water and mounted in Mowiol.
NeuroTrace (fluorescent Nissl stain; Molecular Probes) staining was performed by incubating brain sections for 20 min in a 1:200 dilution of NeuroTrace in TBS. Fluoro-Jade C (a specific marker for degenerating neurons; Chemicon) staining was performed after NeuroTrace as follows. Brain sections were rinsed twice in TBS, re-hydrated for 2 min in distilled water and incubated for 10 min in 0.06% potassium permanganate. Finally, brain sections were washed for 2 min in distilled water and incubated for 10 min in 0.0002% Fluoro-Jade C solution in 0.1% acetic acid. Sections were immediately rinsed in distilled water, mounted, air dehydrated, cleared with xylene and mounted in Entellan.
Cholesterol staining with filipin, a polyene macrolide that binds to free cholesterol, was performed in brain sections that were previously labeled for ChAT by immunohistochemistry . Sections were incubated with filipin (50 μg/mL) in TBS for 2 hrs at RT in the dark. Sections were then washed in TBS for 15 min and mounted in Mowiol.
The cholinergic cell count was performed as described previously . Septal cholinergic neurons were defined using anatomical landmarks in accordance with the mouse brain atlas . The anterior commissure and anterior and lateral ventricles defined the ventral border of the medial septum (MS). The meeting of the body of the corpus callosum at the midline marked the anterior boundary of the MS, and the midline crossing of the anterior commissure and the appearance of the fornix marked the posterior boundary. Four 40-μm-thick coronal sections per mouse were taken through the complete MS with a 160-μm interval between each section to avoid counting the same cells twice (coordinates from BREGMA: 1.10 to 0.5 mm). ChAT-immunopositive cells were counted on images digitized with an Olympus BX51 (Tokyo, Japan) microscope. The criterion for identifying ChAT-immunopositive cells was the appearance of a clear nuclear shape or, in cases when staining was too dark, clear neuronal morphology.
PC12 cells were grown in DMEM containing L-glutamine and high glucose and supplemented with 6% horse serum, 6% fetal calf serum and 100 U/ml penicillin-streptomycin. For differentiation assays, PC12 cells were seeded at a density of 10-15,000 cells per square centimeter on poly-D-lysine-coated 16-mm coverslips and maintained for 24, 48 or 72 hrs in the presence of NGF (5 ng/ml) in DMEM/glutamine/high glucose supplemented with 1 mg/ml BSA. Cells were considered differentiated when they had at least one neurite that was twice the diameter of the cell body.
To reproduce the cellular phenotype of NPC disease, PC12 cells were treated with different concentrations (0.5-2 mg/ml) of the drug U18666A, which causes the accumulation of cholesterol in the late endosomes and lysosomes .
For filipin staining of PC12 cells, cells were fixed for 10 min with cold paraformaldehyde (4%) in PBS, rinsed twice with cold PBS, incubated for 10 min in glycine (150 mM, pH 7.4) and rinsed three times with PBS. After fixation, the cells were permeabilized for 30 min with saponin (0.2%) and BSA (3%) in PBS, incubated for 2 hrs with filipin at RT (90 μg/ml in PBS), rinsed with PBS and mounted in Mowiol.
PC12 cell labeling
For immunostaining of PC12 cells with the lysosomal marker LAMP2, cells were fixed and permeabilized as described above, incubated for 1 hr at RT with a rabbit polyclonal antibody against LAMP2 (1:1000) in PBS containing saponin (0.05%) and BSA (3%) and rinsed three times with PBS. PC12 cells were subsequently incubated in the same buffer containing Alexa Fluor 488-conjugated donkey polyclonal antibody against rabbit IgGs (1:400) for 2 hrs in the presence of filipin, then rinsed and mounted in Mowiol.
For Tau immunostaining of differentiated PC12 cells, cells were seeded as described above for the differentiation assays and maintained for 24 hrs with NGF (5 ng/ml) in DMEM/glutamine/high glucose supplemented with 1 mg/ml BSA. Then, the cells were treated for another 48 hrs with or without U18666A (2 μg/ml) in the same buffer. Tau immunostaining of PC12 cells was performed essentially as described in . Briefly, after treatments, PC12 cells were rinsed with warmed extraction buffer (EB) containing MgCl2 (1 mM), EGTA (1 mM), GTP (1 mM), glycerol (30%) and PIPES buffer (70 mM), pH 6.9; incubated for 30 seconds with EB containing saponin (0.2%); and rinsed again with EB. PC12 cells were then fixed in EB containing paraformaldehyde (2%) and glutaraldehyde (0.2%) for 1 hr at room temperature. This procedure was followed by a rinse with PBS and cell permeabilization in PBS supplemented with Triton X-100 (0.2%) for 2 min. Cells were blocked by treatment with PBS containing BSA (4%). PC12 cells were then incubated with a primary monoclonal antibody against TAU5 (1:100) or AT8 (1:200) overnight at 4°C. PC12 cells were then rinsed and incubated for 90 min at RT with donkey anti-mouse Alexa 488 (TAU5) or Alexa 594 (AT8) antibody, rinsed and mounted in Mowiol.
Transfection of PC12 cells with rabs and imaging
PC12 cells were transfected with Lipofectamine-2000 and plasmids containing the cDNA of Rab5-EGFP or Rab7-EGFP according to the manufacturer's instructions. After 24 hrs, PC12 cells were treated for an additional 24 hrs with or without U18666A (2 μg/ml), fixed and processed for filipin staining as described above.
PC12 cells were transfected with the Rab7-EGFP plasmid and, 24 hrs later, treated with U18666A (2 μg/ml) for 24 hrs in the presence of NGF (to increase cell soma). After treatment, PC12 cells were washed three times with PBS, and the coverslip was inverted in 100 μl of warmed incubation media in a silicon rubber chamber on a microscope slide. Rab7-labeled endosome dynamics were imaged in living cells.
For time-lapse visualization of Rab7-positive endosomes in PC12 cells, Rab7-labeled endosome dynamics were imaged in vivo and digitized by capturing one frame every 0.942 sec for approximately 2 min (a total of 250 frames) with a FluoView software station. Images were captured with an Olympus FluoView 1000 with a filter-type detector confocal microscope mounted on an inverted IX81 motorized microscope. Time-lapse experiments were performed with the 488-nm laser line of a multi-argon laser at 20% transmittance with an UPLS APO100xO 1.4NA oil immersion objective. Images were captured with Olympus Software FV10-SW with a pixel resolution of 512 × 512.
Endocytosis of GM1 and endogenous TrkA in PC12 cells
For endocytosis of GM1 and immunoendocytosis of TrkA, PC12 cells were seeded to a final confluence of 50%, and U18666A (2 μg/ml) was added after 12 hrs. After 24 hrs, PC12 cells were serum-starved for 90 min in 1 mg/ml BSA in DMEM/glutamine/high glucose/HEPES without phenol red (incubation media) and washed with cold PBS. To visualize GM1 accumulation in endosomes, PC12 cells were incubated for 30 min at 37°C with Alexa Fluor 555-conjugated cholera toxin subunit-B (CT-B) (20 μg/ml), washed, fixed and mounted in Mowiol. To visualize the internalization of endogenous TrkA into endosomes, PC12 cells were incubated with 10 μg/ml rabbit TrkA (Upstate) polyclonal antibody in incubation media for 1 hr at 4°C. Then, PC12 cells were incubated for an additional hour with a donkey anti-rabbit Alexa Fluor 488-conjugated antibody (8 μg/ml), washed, and incubated for 2 hrs at 37°C. Cells were then washed, fixed and mounted in Mowiol.
Internalization and recycling of TrkA-flag in PC12 cells
PC12 cells were seeded to a final confluence of 50%. After 12 hrs, U18666A was added (2 μg/ml) for an additional 24 hrs. Lipofectamine-2000 was then used according to the manufacturer's instructions to transfect PC12 cells with a plasmid expressing TrkA with a Flag epitope tag at its amino terminus (TrkA-Flag). After transfection, U18666A (2 μg/ml) was added for an additional 24 hrs. Afterward, PC12 cells were serum-starved for 90 min in incubation media, washed with cold PBS, treated for 15 min at 37°C with Alexa Fluor 488-labeled monoclonal anti-Flag antibody (8.8 μg/ml), washed and incubated for an additional 1 hr and 45 min at 37°C in the presence of NGF (50 ng/ml). For recycling experiments, the anti-Flag Alexa Fluor 488 antibody was allowed to internalize in the presence of NGF for 45 min. Then, PC12 cells were washed with ice-cold EDTA (1 mM) in PBS three times for 3 min (to remove the anti-Flag antibody, as described by ) and incubated with an anti-Alexa Fluor 488 monoclonal antibody (10 μg/ml) for 60 min at 37°C. Finally, PC12 cells were washed, fixed and mounted in Mowiol.
The mouse monoclonal anti-Flag antibody (2.2 mg/ml) was incubated in 0.1 M bicarbonate buffer, pH 9.0, in the presence of Alexa Fluor 488 5-TFP (1 mg/ml) for 60 min at room temperature with gentle stirring with a vortexer. Next, the labeled antibody was purified by gel filtration (Bio-Gel P30, Bio-Rad) in Bio-Spin columns (Bio-Rad).
To measure the fluorescence associated with the perinuclear region of PC12 cells, a concentric circle was drawn using the smallest diameter of the cell with the ImageJ program (National Institutes of Health, USA). Inside this circle, another concentric circle, with half the diameter of the larger circle, was drawn. The fluorescence associated with the smallest circle was considered the perinuclear-associated fluorescence.
To calculate the endosomal volume of TrkA-positive endosomes, a tridimensional reconstruction using the ImageJ program was performed for each cell from Z-Stacks obtained with a confocal microscope. The endosomal volume was calculated by multiplying the larger diameter, the smaller diameter and the thickness of each endosome.
For transferrin loading of PC12 cells, cells were serum-starved for 90 min in incubation media and treated for 2 hrs at 37°C with Alexa Fluor 568-labeled transferrin (10 μg/ml or 60 μg/ml) in the same culture medium. Cells were then rinsed with PBS, fixed and mounted in Mowiol.
Kinetics of NGF-activated signaling pathways in control and PC12-U18666A cells
PC12 cells at high density (70%) were grown on 3-cm plates in complete media and treated with U18666A (2 μg/ml) for 24 hrs. PC12 cells were then serum-starved for 2 hrs in DMEM/glutamine/high glucose-containing BSA (1 mg/ml) and treated for different durations (0-360 min) in the same media with NGF (5 ng/ml) in the presence of U18666A. To stop the treatment, PC12 cells were rinsed with cold PBS and lysed for 30 min in ice-cold lysis buffer [HEPES (50 mM), NaCl (150 mM), EGTA (1 mM), MgCl2 (5 mM), glycerol (10%) and Triton X-100 (1%)] supplemented with protease and phosphatase inhibitor cocktails. The PC12 supernatant was obtained after centrifugation, and proteins were measured using the Bio-Rad DC protein assay. Western blotting was performed with antibodies specific for phospho- and total Akt, ERK1/2 and PLC. Detection was performed with HRP-conjugated secondary antibodies and the West Pico ECL kit (Pierce). To measure ChAT, pAkt and Akt levels in the brain, the medial septum of WT and NPC1-/- mice was micro-dissected and homogenized in cold lysis buffer supplemented with protease and phosphatase inhibitor cocktails. The brain tissue supernatant was obtained after centrifugation, and proteins were measured with the Bio-Rad DC protein assay. Western blotting was performed with specific antibodies, and detection was carried out with HRP-conjugated secondary antibodies and the West Pico ECL kit (Pierce).
PC12 cells seeded in 10-cm plates were treated as described above for the activation of NGF signaling pathways. PC12 cells were then washed with ice-cold PBS and lysed with buffer containing Tris (20 mM) pH 8.0, NaCl (150 mM), Igepal (1%), glycerol (10%) and EDTA (2 mM) and supplemented with protease and phosphatase inhibitor cocktails. Immunoprecipitation was performed as described previously .
Optical and fluorescent microscopy were performed with brain sections and PC12 cells. Most of the digitized images were obtained with an Olympus BX51 (Tokyo, Japan) optical microscope (20× objective) equipped with a CoolSnap-Pro digital camera (Media Cybernetics, Maryland, USA) and connected to an image analysis system based on the Image-Pro Express software, version 220.127.116.11 (Media Cybernetics). The pictures were analyzed with SigmaScan software (SPSS; Chicago, Illinois, USA). Panoramic views of the MS were obtained with a 20× objective. Amplified images were taken with a 63× objective. Image analysis of PC12-related pictures was performed with the public-domain Image J 1.43 software.
ChAT levels in septal cholinergic neurons were quantified in images digitized by an Olympus IX71 inverted microscope equipped with a QImaging QICAM Fast 1394 digital camera and connected to an image analysis system based on the Image-Pro Express software (version 18.104.22.1681, Media Cybernetics). Images of the septal areas from three animals per treatment (two coronal sections per animal) were analyzed. Images were digitally inverted, and the integrated intensity was measured for each ChAT immunopositive cell using the ImageJ software. For each treatment, the values of integrated intensity were averaged and compared with Student's t-test over a total of 180 cells per treatment in the case of ChAT and 54-61 cells in the case of TrkA. The total intensities of the ChAT and TrkA immunohistochemical or immunofluorescent levels per cell were standardized by the total size of the neuron that was quantified.
Confocal images from p75-labeled brain sections were collected using a Zeiss LSM Pascal 5 [including a triple laser module (Arg 458/488/514 nm, HeNe 543 nm, HeNe 633 nm; Carl Zeiss, Thornwood, NY)] connected to an inverted microscope (Axiovert 2000) with a 63× objective. Confocal images of ChAT-, NeuroTrace- and Fluoro-Jade C-labeled brain sections from axotomized brains were collected with a Olympus FluoView 1000 with a filter-type detector confocal microscope mounted on an inverted IX81 motorized microscope. Pictures of the septal areas from three animals per treatment (two coronal sections per animal) were analyzed to measure the intensity of ChAT staining and to quantify the number of NeuroTrace-positive neurons. For ChAT staining, images were digitally inverted, and the integrated intensity was measured for each ChAT-immunopositive cell with the ImageJ software. For each treatment, the values of the integrated intensities were averaged and compared with Student's t-test over a total of 92 ChAT-positive cells in the contralateral side of the axotomy and 40-43 ChAT-positive cells in the ipsilateral side of the axotomy. The number of neurons positive for NeuroTrace was manually counted from the digitized images. Only the cells that were inside a grid as shown in Additional file 1: Figure S1 were considered.
Data analysis of brain sections and PC12-related experiments
Comparisons between the axotomized and unlesioned sides of the septum were statistically validated by Student's t-test to determine the level of significance (p < 0.05). The analyses were performed using the septum contralateral to the lesioned side as a control (100%).
Comparisons between control and PC12-U18666A cells were statistically validated by Student's t-test (or two-way ANOVA) to determine the level of significance, as indicated in the figure legends.
We used two different models to assess whether the NPC1 deficiency and endosomal abnormalities caused by cholesterol accumulation in the late endocytic pathway disrupted NGF signaling. First, we studied NGF signaling in vivo using the septo-hippocampal pathway, which responds to NGF after axotomy, by stabilizing the levels of choline acetyl transferase (ChAT) in axotomized cholinergic neurons. In addition, we established a cell culture model of NPC by treating PC12 cells with the drug U18666A.
These observations indicate that although NPC1-/- cholinergic neurons had morphological abnormalities, they were not more vulnerable to axotomy than WT neurons. These results are consistent with our recently published observations showing a lack of degeneration of MS cholinergic neurons after axotomy in rats . Although axotomy causes similar cholinergic neuronal loss in the MS of WT and NPC1-/- mice, we quantified the intensity of ChAT immunofluorescence from cholinergic cells in the contralateral and ipsilateral sides of the MS 7 days after axotomy. We observed that the cholinergic cells of the contralateral side of the axotomy had similar levels of ChAT staining in NPC1-/- mice and WT mice; however, the cholinergic cells of the ipsilateral side of the lesion in the MS had increased staining for ChAT in NPC1-/- mice compared to WT mice (Figure 2C and 2D). We also observed increased ChAT levels in MS homogenates from NPC1-/- mice compared to WT mice (Figure 2E). Because chat is under the control of NGF signaling, these results suggest an increased response to endogenous NGF [47, 48]. Finally, to determine whether axotomized MS cholinergic neurons in NPC1-/- mice respond to NGF in vivo, we infused WT and NPC1-/- mouse brains with NGF for 7 days starting after the surgery. Surprisingly, NPC1-/- cholinergic neurons responded similarly to WT neurons in response to the lesion and NGF treatment, with protection of approximately 80% of axotomized cholinergic neurons (Figures 2F and 2G). The reduction of AChE staining in the whole hippocampus was similar in WT and NPC1-/- mice (Additional file 4: Figure S4D and F). However, consistent with the suggestion that NPC-/- cholinergic neurons have an increased response to NGF, the axotomized cholinergic neurons from NGF-infused NPC1-/- mice exhibited increased ChAT staining compared to WT in the contralateral and ipsilateral sides of the lesions (Figure 2F and 2H). Because we found similar levels of AChE in the hippocampus of non-axotomized NPC1-/- mice (Additional file 4: Figure S4A and B), we hypothesize that the increase in ChAT after NGF infusion was not due to altered anterograde axonal transport in cholinergic cells from NPC1-/- mice but to an increased response to exogenous NGF. Altogether, these results suggest that cholinergic neurons from NPC1-/- mice are more sensitized to NGF than those from WT mice.
To further elucidate the mechanism by which NPC1-/- cholinergic neurons are sensitized to NGF signaling, we established a cell culture model of NPC by treating PC12 cells with the drug U18666A. PC12 cells are a good model in which to study NGF signaling because they express p75 and TrkA and respond to NGF by differentiating into a sympathetic-like neuron [30, 31]. Treating PC12 cells with increasing concentrations of U18666A for 24 hrs resulted in a gradual accumulation of free cholesterol inside the cells, as measured by filipin staining. In addition, similarly to other NPC1 cellular models, PC12 cells treated with U18666A (PC12-U18666A) exhibited cholesterol and ganglioside GM1 accumulation and increased cell size as a result of cholesterol overload. Similarly to other NPC1 models, PC12-U18666A exhibited a change in the distribution pattern of late endosomes, yielding a structure similar to a ring filled with free cholesterol and with reduced mobility (Additional file 5: Figure S5, Additional file 6: Figure S6) [13, 16, 49–52]. All of these results indicate that PC12 cells treated with the drug U18666A are a good model for assessing the different cellular and molecular consequences of the NPC1 phenotype related to NGF signaling.
Taken together, our results suggest that NPC1-/- cholinergic cells are sensitized to NGF compared to WT neurons, which correlates with the increased NGF response in PC12-U18666A. In addition, these results show that NPC1-/-cholinergic neurons, despite obvious morphological abnormalities, were able to respond to NGF in vivo.
Our study emphasizes the role of anomalous neurotrophin signaling in the neuropathology of NPC and is the first to demonstrate neuropathological changes in the septal cholinergic system of the basal forebrain in NPC1-/- mice. Although several kinases are up-regulated in NPC brains [54–57], to the best of our knowledge, this is the first time that up-regulation of a kinase, particularly Akt, has been linked to a specific signaling transduction pathway such as NGF signaling in NPC.
The goal of our research was to investigate whether NGF signaling is affected in NPC1 disease in two models known to respond to NGF. Initially, we analyzed NGF signaling in vivo by infusing the brains of axotomized NPC1-/- and WT mice with NGF. MS cholinergic neurons from NPC1-/- mice responded to NGF in vivo and had increased ChAT staining after NGF infusion compared to WT mice. Although the increased expression of ChAT was readily evident in NGF-infused mice, increased ChAT expression was also detected in the presence of endogenous levels of NGF in the ipsilateral side of axotomized NPC1-/- mice compared to the WT mice. In this case, ChAT levels were measured by immunofluorescence; however, increased ChAT levels were also evident in non-axotomized NPC1-/- mice when the ChAT levels in MS homogenates from NPC1-/- mice were compared to WT mice by western blotting. We also found an increased amount of phosphorylated Akt in the medial septum of non-axotomized NPC1-/- mice compared to WT mice. These observations support the regulation of ChAT gene transcription by TrkA activation, particularly through the Akt signaling pathway, as described previously [47, 48]. The increased Akt phosphorylation found in NGF-treated PC12-U18666A cells (see below) may partly explain the increased ChAT levels in NPC1-/- MS cholinergic neurons.
The conserved response to NGF in NPC1-/- mice was surprising because we found that the morphological alterations of MS cholinergic neurons in NPC1-/- mice were similar to those of neurons from different brain regions, such as brain stem neurons, of patients with NPC disease . Purkinje cell loss is a prominent feature of the NPC1-/- mouse model, and some Purkinje cells exhibit a severely stunted or retracted dendritic arbor before neuronal death . These observations, together with our findings in MS cholinergic neurons, suggest that dendritic alterations precede neuronal loss as a general feature of neurodegeneration in the NPC brain. These results also explain the reduced vulnerability of cholinergic neurons compared to Purkinje cells because cholinergic neurons receive additional trophic support from hippocampal neurons and oligodendrocytes [60–63]. Although cholinergic neurons may be more protected than Purkinje cells temporarily, the chronic up-regulation of NGF signaling pathways, such as Akt, may lead to abnormal phosphorylation of cytoskeletal proteins. Consistent with this idea, several kinases, including ERK1/2, CDK5, c-Abl, and PI3K, are up-regulated in the brains of NPC1-/- mice [54–57].
To gain greater insight into the effect of NPC1 inhibition and cholesterol overload in the endocytic pathway on NGF signaling, we established a cell culture model of NPC by treating PC12 cells with the drug U18666A. As expected, PC12-U18666A cells fully recapitulated the key characteristics of the cellular phenotype of cells from NPC patients and cellular models of NPC disease, such as increased cholesterol, endosomal abnormalities and GM1 accumulation [50, 64]. Although U18666A is a pharmacological tool and its use may induce other cellular changes that are not related to the down-regulation of NPC1 function (see review by ), we found that, at the cellular level, PC12-U18666A cells mirrored the phenotype of other NPC cellular models . One general observation in PC12-U18666A cells was that there were profound changes in the distribution of endosomes. These changes could have been the result of the misregulation of Rab activities. Rab proteins are small monomeric GTPases that regulate many steps of membrane trafficking, including vesicle formation, vesicle movement along actin microfilament and microtubules and membrane fusion . In cellular models of NPC disease, cholesterol overload influences the retrieval of Rab proteins (Rab4, Rab5, Rab9 and Rab7) from different endosomal membranes, which leads to the sequestration of Rabs in inactive forms [13–15] and disturbs the movement of vesicles along microtubules by influencing molecular motor activity . Therefore, the changes in the endosomal distribution in PC12-U18666A cells may be related to altered transport and maturation of these endosomes as a result of the misregulation of motor proteins.
PC12-U18666A cells treated for two days with low concentrations of NGF exhibited greater differentiation and more and longer neurites than control cells, indicating that PC12-U18666A cells are more sensitized to NGF. This result correlated with an up-regulation of Akt and PLC-γ signaling but not ERK1/2 when PC12-U18666A cells were treated with NGF for short durations (15 min-6 hrs). Akt and PLC-γ signaling regulate neuronal morphology in different neuronal types, including PC12 cells, consistent with increased NGF-induced differentiation in PC12-U18666A cells [66–68]. The differentiation process in PC12 cells is measured by quantifying cells that possess neurites that are twice the diameter of the cell body. Therefore, it is difficult to separate the process of differentiation from the process of neurite growth. Therefore, we treated PC12 cells with U18666A then with NGF. Under these conditions, we observed increased neurite length but not increased differentiation. In addition, neurite growth of differentiated PC12 cells was inhibited by a specific inhibitor of the IP3K-Akt pathway (wortmannin). Taken together, these data suggest that the treatment of PC12 cells with U18666A increases IP3K-Akt signaling in response to NGF-induced increased neurite growth. Differentiated PC12 cells die after 48 hrs of U18666A treatment, and PC12-U18666A cells treated for 48 hrs with NGF show increased AT8 phosphorylation, suggesting that the increase in NGF signaling induced by U18666A treatment is related to a pathological process rather than a survival signal. The increase in Akt signaling in PC12-U18666A cells treated with NGF correlates with increased levels of phosphorylated Akt in the MS of NPC1-/- mice compared to WT mice. Cholinergic neurons located in the MS normally respond to NGF signaling by increasing ChAT synthesis, suggesting that the inhibition of NPC1 may also cause increased NGF-signaling in vivo.
The AT8 antibody is one of the most widely used antibodies against phosphorylated tau and recognizes neurofibrillary lesions in several neurodegenerative disorders . Interestingly, up-regulation of Akt in AD brains has been correlated with the presence of AT8 immunoreactivity . Taken together, these results suggest that, rather than inducing survival, the chronic up-regulation of signaling pathways such as Akt in post-mitotic neurons may ultimately misregulate other signaling pathways, leading to abnormal phosphorylation of the cytoskeleton and neuronal degeneration.
Several lines of evidence suggest that the abnormal recycling of receptors may play a role in abnormal signaling and trafficking of receptors in NPC. For example, the impairment of transferrin and lipid recycling has been observed in cellular NPC models , and the impairment of Rab function has been proposed to cause normal influx but slower efflux of components in the endocytic compartment [50, 71]. Indeed, consistent with a receptor recycling problem in NPC cells, we found an abnormal distribution of early and recycling endosomes, increased TrkA-positive endosome size and reduced recycling of the TrkA receptor in PC12-U18666A cells. Along with the observation of Lee et al.  that NGF-induced long-lasting activation of Akt signaling depends on TrkA receptor recycling, our results suggest that the increased Akt activation in both NPC models may be due, at least in part, to reduced recycling of the TrkA receptor. This phenomenon could also explain why TrkB activation is inhibited in striatal neurons derived from NPC1-/- mice; TrkB has reduced recycling capacities than TrkA and thus it is affected differently by the accumulation of cholesterol [12, 38]. Or alternatively, TrkB may be more sensitive than TrkA to changes in the cholesterol content of the plasma membrane . Both of these scenarios would give rise to different responses to downstream signaling by TrkA and TrkB in the context of the NPC phenotype .
We have demonstrated for the first time that the endosomal alterations caused by NPC result in the up-regulation of a specific signaling pathway. Some of the neurodegenerative changes observed in NPC may be due to misregulation of the signaling networks that normally control proper neuronal physiological function.
The authors gratefully acknowledge financial support from FONDAP CRCP (13980001), CARE (CONICYT PFB12/2007), the Ara Parseghian Medical Research Foundation, FONDECYT 1040799 (FB), 1085273 (FB), 1070622 (SZ), F1080221 (AA), 1095089 (CGB), Proyecto Núcleo Milenio (MINREB) P07/011-F and ICM P05-001-F (CGB).
- Miller FD, Kaplan DR: On Trk for retrograde signaling. Neuron. 2001, 32 (5): 767-770. 10.1016/S0896-6273(01)00529-3.PubMedGoogle Scholar
- Chao MV, Lee FS: Neurotrophin survival signaling mechanisms. J Alzheimers Dis. 2004, 6 (6 Suppl): S7-S11.PubMedGoogle Scholar
- Huang EJ, Reichardt LF: TRK receptors: roles in neuronal signal transduction. Annu Rev Biochem. 2003, 72 (7): 609-642.PubMedGoogle Scholar
- Lu B, Pang PT, Woo NH: The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005, 6 (8): 603-614. 10.1038/nrn1726.PubMedGoogle Scholar
- Zweifel LS, Kuruvilla R, Ginty DD: Functions and mechanisms of retrograde neurotrophin signalling. Nat Rev Neurosci. 2005, 6 (8): 615-625. 10.1038/nrn1727.PubMedGoogle Scholar
- Bronfman FC, et al: Endosomal transport of neurotrophins: roles in signaling and neurodegenerative diseases. Dev Neurobiol. 2007, 67 (9): 1183-1203. 10.1002/dneu.20513.PubMedGoogle Scholar
- Perlson E, et al: Retrograde axonal transport: pathways to cell death?. Trends Neurosci. 2010, 33 (7): 335-344. 10.1016/j.tins.2010.03.006.PubMed CentralPubMedGoogle Scholar
- Vanier MT, Millat G: Niemann-Pick disease type C. Clin Genet. 2003, 64 (4): 269-281. 10.1034/j.1399-0004.2003.00147.x.PubMedGoogle Scholar
- Liscum L, Klansek JJ: Niemann-Pick disease type C. Curr Opin Lipidol. 1998, 9 (2): 131-135. 10.1097/00041433-199804000-00009.PubMedGoogle Scholar
- Sturley SL, et al: The pathophysiology and mechanisms of NP-C disease. Biochim Biophys Acta. 2004, 1685 (1-3): 83-87.PubMedGoogle Scholar
- Paul CA, Boegle AK, Maue RA: Before the loss: neuronal dysfunction in Niemann-Pick Type C disease. Biochim Biophys Acta. 2004, 1685 (1-3): 63-76.PubMedGoogle Scholar
- Henderson LP, et al: Embryonic striatal neurons from niemann-pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness. J Biol Chem. 2000, 275 (26): 20179-20187. 10.1074/jbc.M001793200.PubMedGoogle Scholar
- Ganley IG, Pfeffer SR: Cholesterol accumulation sequesters Rab9 and disrupts late endosome function in NPC1-deficient cells. J Biol Chem. 2006, 281 (26): 17890-17899. 10.1074/jbc.M601679200.PubMed CentralPubMedGoogle Scholar
- Choudhury A, et al: Elevated endosomal cholesterol levels in Niemann-Pick cells inhibit rab4 and perturb membrane recycling. Mol Biol Cell. 2004, 15 (10): 4500-4511. 10.1091/mbc.E04-05-0432.PubMed CentralPubMedGoogle Scholar
- Lebrand C, et al: Late endosome motility depends on lipids via the small GTPase Rab7. EMBO J. 2002, 21 (6): 1289-1300. 10.1093/emboj/21.6.1289.PubMed CentralPubMedGoogle Scholar
- Zhang M, et al: Cessation of rapid late endosomal tubulovesicular trafficking in Niemann-Pick type C1 disease. Proc Natl Acad Sci USA. 2001, 98 (8): 4466-4471. 10.1073/pnas.081070898.PubMed CentralPubMedGoogle Scholar
- Amritraj A, et al: Increased activity and altered subcellular distribution of lysosomal enzymes determine neuronal vulnerability in Niemann-Pick type C1-deficient mice. Am J Pathol. 175 (6): 2540-2556.Google Scholar
- Liu K, et al: PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci. 2010, 13 (9): 1075-1081. 10.1038/nn.2603.PubMed CentralPubMedGoogle Scholar
- Nixon RA: Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am J Pathol. 2004, 164 (3): 757-761. 10.1016/S0002-9440(10)63163-X.PubMed CentralPubMedGoogle Scholar
- Patterson MC, et al: Niemann-Pick disease type C. A lipid trafficking disorder. The metabolic and molecular basis of inherited disease. Edited by: Scriver CR, et al. 2001, New York: Mulencer Hill, II: 8Google Scholar
- Hasselmo ME: The role of acetylcholine in learning and memory. Curr Opin Neurobiol. 2006, 16 (6): 710-5. 10.1016/j.conb.2006.09.002.PubMed CentralPubMedGoogle Scholar
- Conner JM, Chiba AA, Tuszynski MH: The basal forebrain cholinergic system is essential for cortical plasticity and functional recovery following brain injury. Neuron. 2005, 46 (2): 173-179. 10.1016/j.neuron.2005.03.003.PubMedGoogle Scholar
- Sofroniew MV, et al: Survival of adult basal forebrain cholinergic neurons after loss of target neurons. Science. 1990, 247 (4940): 338-342. 10.1126/science.1688664.PubMedGoogle Scholar
- Voytko ML, et al: Basal forebrain lesions in monkeys disrupt attention but not learning and memory. J Neurosci. 1994, 14 (1): 167-186.PubMedGoogle Scholar
- Bierer LM, et al: Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem. 1995, 64 (2): 749-760.PubMedGoogle Scholar
- Geula C, Mesulam M: Cholinergic Systems and Related Neuropathological Predilection Patterns in Alzheimer's Disease. Alzheimer's Disease. Edited by: Terry R, Kaltzman R, Bick K. 1994, New York: Raven Press, Ltd, Chapter 15: 263-291.Google Scholar
- Winkler J, et al: Cholinergic strategies for Alzheimer's disease. J Mol Med. 1998, 76 (8): 555-567. 10.1007/s001090050250.PubMedGoogle Scholar
- Koh CH, Cheung NS: Cellular mechanism of U18666A-mediated apoptosis in cultured murine cortical neurons: bridging Niemann-Pick disease type C and Alzheimer's disease. Cell Signal. 2006, 18 (11): 1844-1853. 10.1016/j.cellsig.2006.04.006.PubMedGoogle Scholar
- Liscum L, Faust JR: The intracellular transport of low density lipoprotein-derived cholesterol is inhibited in Chinese hamster ovary cells cultured with 3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one. J Biol Chem. 1989, 264 (20): 11796-11806.PubMedGoogle Scholar
- Greene LA, Tischler AS: Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA. 1976, 73 (7): 2424-2428. 10.1073/pnas.73.7.2424.PubMed CentralPubMedGoogle Scholar
- Cenedella RJ: Cholesterol synthesis inhibitor U18666A and the role of sterol metabolism and trafficking in numerous pathophysiological processes. Lipids. 44 (6): 477-487.Google Scholar
- Amigo L, et al: Hepatic overexpression of sterol carrier protein-2 inhibits VLDL production and reciprocally enhances biliary lipid secretion. J Lipid Res. 2003, 44 (2): 399-407. 10.1194/jlr.M200306-JLR200.PubMedGoogle Scholar
- Paxinos G, Watson C: The rat brain in stereotaxic coordinates. ed1998, San Diego: Academic Press. xxvi,  of plates, 4Google Scholar
- Gage FH, et al: Morphological response of axotomized septal neurons to nerve growth factor. J Comp Neurol. 1988, 269 (1): 147-155. 10.1002/cne.902690112.PubMedGoogle Scholar
- Bronfman FC, Moechars D, Van Leuven F: Acetylcholinesterase-positive fiber deafferentation and cell shrinkage in the septohippocampal pathway of aged amyloid precursor protein london mutant transgenic mice. Neurobiol Dis. 2000, 7 (3): 152-168. 10.1006/nbdi.2000.0283.PubMedGoogle Scholar
- Drabikowski W, Lagwinska E, Sarzala MG: Filipin as a fluorescent probe for the location of cholesterol in the membranes of fragmented sarcoplasmic reticulum. Biochim Biophys Acta. 1973, 291 (1): 61-70. 10.1016/0005-2736(73)90060-6.PubMedGoogle Scholar
- Shelton SB, Johnson GV: Tau and HMW tau phosphorylation and compartmentalization in apoptotic neuronal PC12 cells. J Neurosci Res. 2001, 66 (2): 203-213. 10.1002/jnr.1212.PubMedGoogle Scholar
- Chen ZY, et al: A novel endocytic recycling signal distinguishes biological responses of Trk neurotrophin receptors. Mol Biol Cell. 2005, 16 (12): 5761-5772. 10.1091/mbc.E05-07-0651.PubMed CentralPubMedGoogle Scholar
- Bronfman FC, et al: Ligand-induced internalization of the p75 neurotrophin receptor: a slow route to the signaling endosome. J Neurosci. 2003, 23 (8): 3209-3220.PubMedGoogle Scholar
- Lazo OM, et al: Axotomy-induced neurotrophic withdrawal causes the loss of phenotypic differentiation and downregulation of NGF signalling, but not death of septal cholinergic neurons. Mol Neurodegener. 2010, 5: 5-10.1186/1750-1326-5-5.PubMed CentralPubMedGoogle Scholar
- Vance JE, Hayashi H: Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta. 2010, 1801 (8): 806-818.PubMedGoogle Scholar
- Beirowski B, et al: Mechanisms of axonal spheroid formation in central nervous system Wallerian degeneration. J Neuropathol Exp Neurol. 2010, 69 (5): 455-472. 10.1097/NEN.0b013e3181da84db.PubMedGoogle Scholar
- van der Zee CE, Hagg T: Delayed NGF infusion fails to reverse axotomy-induced degeneration of basal forebrain cholinergic neurons in adult p75(LNTR)-deficient mice. Neuroscience. 2002, 110 (4): 641-651. 10.1016/S0306-4522(01)00606-6.PubMedGoogle Scholar
- Armstrong DM, et al: Response of septal cholinergic neurons to axotomy. J Comp Neurol. 1987, 264 (3): 421-436. 10.1002/cne.902640309.PubMedGoogle Scholar
- Naumann T, Peterson GM, Frotscher M: Fine structure of rat septohippocampal neurons: II. A time course analysis following axotomy. J Comp Neurol. 1992, 325 (2): 219-242. 10.1002/cne.903250207.PubMedGoogle Scholar
- Schmued LC, et al: Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Res. 2005, 1035 (1): 24-31. 10.1016/j.brainres.2004.11.054.PubMedGoogle Scholar
- Silver MA, et al: Infusion of nerve growth factor (NGF) into kitten visual cortex increases immunoreactivity for NGF, NGF receptors, and choline acetyltransferase in basal forebrain without affecting ocular dominance plasticity or column development. Neuroscience. 2001, 108 (4): 569-585. 10.1016/S0306-4522(01)00391-8.PubMed CentralPubMedGoogle Scholar
- Madziar B, et al: Regulation of cholinergic gene expression by nerve growth factor depends on the phosphatidylinositol-3'-kinase pathway. J Neurochem. 2005, 92 (4): 767-779. 10.1111/j.1471-4159.2004.02908.x.PubMedGoogle Scholar
- Lusa S, et al: Depletion of rafts in late endocytic membranes is controlled by NPC1-dependent recycling of cholesterol to the plasma membrane. J Cell Sci. 2001, 114 (Pt 10): 1893-1900.PubMedGoogle Scholar
- Sugimoto Y, et al: Accumulation of cholera toxin and GM1 ganglioside in the early endosome of Niemann-Pick C1-deficient cells. Proc Natl Acad Sci USA. 2001, 98 (22): 12391-12396. 10.1073/pnas.221181998.PubMed CentralPubMedGoogle Scholar
- Ko DC, et al: Dynamic movements of organelles containing Niemann-Pick C1 protein: NPC1 involvement in late endocytic events. Mol Biol Cell. 2001, 12 (3): 601-614.PubMed CentralPubMedGoogle Scholar
- Lange Y, et al: Dynamics of lysosomal cholesterol in Niemann-Pick type C and normal human fibroblasts. J Lipid Res. 2002, 43 (2): 198-204.PubMedGoogle Scholar
- Treiber-Held S, et al: Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann-Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer's disease. J Pathol. 2003, 200 (1): 95-103. 10.1002/path.1345.PubMedGoogle Scholar
- Bi X, et al: Deregulation of the phosphatidylinositol-3 kinase signaling cascade is associated with neurodegeneration in Npc1-/- mouse brain. Am J Pathol. 2005, 167 (4): 1081-1092. 10.1016/S0002-9440(10)61197-2.PubMed CentralPubMedGoogle Scholar
- Alvarez AR, et al: Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease. FASEB J. 2008, 22 (10): 3617-3627. 10.1096/fj.07-102715.PubMedGoogle Scholar
- Sawamura N, et al: Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem. 2001, 276 (13): 10314-10319. 10.1074/jbc.M009733200.PubMedGoogle Scholar
- Bu B, et al: Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci. 2002, 22 (15): 6515-6525.PubMedGoogle Scholar
- Pacheco CD, Lieberman AP: The pathogenesis of Niemann-Pick type C disease: a role for autophagy?. Expert Rev Mol Med. 2008, 10: e26-PubMed CentralPubMedGoogle Scholar
- Sarna JR, et al: Patterned Purkinje cell degeneration in mouse models of Niemann-Pick type C disease. J Comp Neurol. 2003, 456 (3): 279-291. 10.1002/cne.10522.PubMedGoogle Scholar
- Dai X, et al: The trophic role of oligodendrocytes in the basal forebrain. J Neurosci. 2003, 23 (13): 5846-5853.PubMedGoogle Scholar
- Hefti F: Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci. 1986, 6 (8): 2155-2162.PubMedGoogle Scholar
- Lopez-Coviella I, et al: Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9. Science. 2000, 289 (5477): 313-316. 10.1126/science.289.5477.313.PubMedGoogle Scholar
- Morse JK, et al: Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J Neurosci. 1993, 13 (10): 4146-4156.PubMedGoogle Scholar
- Peake KB, Vance JE: Defective cholesterol trafficking in Niemann-Pick C-deficient cells. FEBS Lett. 2010, 584 (13): 2731-2739. 10.1016/j.febslet.2010.04.047.PubMedGoogle Scholar
- Jordens I, et al: Rab proteins, connecting transport and vesicle fusion. Traffic. 2005, 6 (12): 1070-1077. 10.1111/j.1600-0854.2005.00336.x.PubMedGoogle Scholar
- Rong R, et al: Phospholipase activity of phospholipase C-gamma1 is required for nerve growth factor-regulated MAP kinase signaling cascade in PC12 cells. J Biol Chem. 2003, 278 (52): 52497-52503. 10.1074/jbc.M306744200.PubMedGoogle Scholar
- Pilpel Y, Segal M: Activation of PKC induces rapid morphological plasticity in dendrites of hippocampal neurons via Rac and Rho-dependent mechanisms. Eur J Neurosci. 2004, 19 (12): 3151-3164. 10.1111/j.0953-816X.2004.03380.x.PubMedGoogle Scholar
- Read DE, Gorman AM: Involvement of Akt in neurite outgrowth. Cell Mol Life Sci. 66 (18): 2975-2984.Google Scholar
- Goedert M, Jakes R, Vanmechelen E: Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett. 1995, 189 (3): 167-169. 10.1016/0304-3940(95)11484-E.PubMedGoogle Scholar
- Pei JJ, et al: Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol. 2003, 105 (4): 381-392.PubMedGoogle Scholar
- Neufeld EB, et al: The Niemann-Pick C1 protein resides in a vesicular compartment linked to retrograde transport of multiple lysosomal cargo. J Biol Chem. 1999, 274 (14): 9627-9635. 10.1074/jbc.274.14.9627.PubMedGoogle Scholar
- Guirland C, et al: Lipid rafts mediate chemotropic guidance of nerve growth cones. Neuron. 2004, 42 (1): 51-62. 10.1016/S0896-6273(04)00157-6.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.